Continuous Glucose Monitoring (CGM) in an Underserved Population
The investigators aim is to conduct a randomized clinical trial in an underserved population who are either uninsured or on Medicaid and taking at least one injection of insulin daily. The investigators believe that this study will lead to considerable alleviation of health disparities and provide better care for an underserved population. This will be a pilot study to evaluate the feasibility of such a trial in this population before doing a larger multicenter trial.
Conditions studied
Diabetes, Diabetes Mellitus, Diabetes Type 2
About this study
The investigators aim is to conduct a randomized clinical trial in an underserved population who are either uninsured or on Medicaid and taking at least one injection of insulin daily. The investigators believe that this study will lead to considerable alleviation of health disparities and provide better care for an underserved population. This will be a pilot study to evaluate the feasibility of such a trial in this population before doing a larger multicenter trial.
Interventions
- Device: Continuous Glucose Monitoring (CGM) — Continuous glucose monitors will be placed subcutaneously every 14 days.
Primary outcomes
- Change in Glycated hemoglobin (HbA1c) between baseline and 6-month visits for both groups (Baseline, 6 months)
Eligibility information
Study locations
- University Medical Center, New Orleans, Louisiana 70112 United States
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.